Related Experiment Video

Updated: Jun 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats

Lamia Raaf1, Christophe Noll2, Mohamed Cherifi3

  • 1University Paris Diderot-CNRS EAC 4413, Unit of Functional and Adaptive Biology (BFA), Paris, France; Laboratory of Biochemistry and Extracellular Matrix Remodeling, BCM.FSB.USTHB, Algiers, Algeria.

International Journal of Cardiology
|November 13, 2009
PubMed

Insights

Hyperhomocysteinemia induces cardiac hypertrophy in rats by decreasing the expression of DYRK1A, a key kinase involved in heart function. This reduction may impair the protective effects of DYRK1A, contributing to heart failure risk.

Area of Science:

  • Cardiovascular biology
  • Molecular cardiology
  • Biochemistry

Background:

  • Hyperhomocysteinemia is a significant risk factor for chronic heart failure.
  • Cardiac hypertrophy, an enlargement of heart muscle, is a precursor to heart failure.
  • The serine-threonine kinase DYRK1A plays a role in molecular pathways leading to cardiac hypertrophy.

Purpose of the Study:

  • To investigate the expression of DYRK1A in the hearts of hyperhomocysteinemic rats.
  • To determine the relationship between hyperhomocysteinemia, cardiac hypertrophy, and DYRK1A expression.

Main Methods:

  • Induction of hyperhomocysteinemia in a rat model.
  • Assessment of ventricular cardiomyocyte size and morphology.
  • Quantification of protein expression levels of DYRK1A in cardiac tissue.

Main Results:

  • Hyperhomocysteinemia induced significant ventricular cardiomyocyte hypertrophy in rats.
  • Protein expression of DYRK1A was decreased in the hearts of hyperhomocysteinemic rats.
  • The observed decrease in DYRK1A expression correlated with the development of cardiac hypertrophy.

Conclusions:

  • Decreased DYRK1A expression in hyperhomocysteinemic rats may contribute to cardiac hypertrophy.
  • Reduced DYRK1A levels could diminish its antihypertrophic effects, exacerbating heart condition.
  • DYRK1A warrants further investigation as a potential therapeutic target for hyperhomocysteinemia-related heart disease.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...